Last update 05 Jun 2025

Interleukin-7(Cytheris SA)

Overview

Basic Info

Drug Type
Interleukins
Synonyms
Glycosylated recombinant human interleukin-7, IL-7, Interleukin 7
+ [10]
Target
Action
agonists, modulators
Mechanism
IL-7Rα agonists(Interleukin-7 receptor subunit alpha agonists), Immunomodulators
Active Indication
Originator Organization
Active Organization
Inactive Organization
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPhase 2
United States
30 Jan 2022
COVID-19Phase 2
Brazil
01 Mar 2021
Mycobacterium Avium-Intracellulare InfectionPhase 2
United States
30 Nov 2020
COVID-19 omicron variant infectionPhase 2
United Kingdom
14 May 2020
SepsisPhase 2
United States
01 Jun 2019
Shock, SepticPhase 2
United States
01 Jan 2016
LymphopeniaPhase 2
France
01 Jun 2011
Metastatic breast cancerPhase 2
France
01 Jun 2011
HIV InfectionsPhase 2
United States
01 Jan 2010
HIV InfectionsPhase 2
Canada
01 Jan 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(Mesothelin (MSLN)-CAR (M))
kyiahwwsqq(rohaglhhir) = ilesefnwse mxankarhls (rjcxzuiquo )
-
27 Apr 2025
(MSLN-CAR secreting IL7 (M7))
kyiahwwsqq(rohaglhhir) = jhckjnosjv mxankarhls (rjcxzuiquo )
Phase 2
47
(Group 1 (CYT107, Atezolizumab))
htilahpfjo = xzttsgboyu zajkwttfna (fddnsatman, qnrjfclusr - fxpbvtvywo)
-
03 Jul 2024
Computed Tomography+Atezolizumab
(Group 2 (Atezolizumab))
htilahpfjo = dkswwyxhzb zajkwttfna (fddnsatman, dllbilvmzc - zbaubocrhi)
Phase 2
47
hyzunwhesy(bavafnbmad) = kcvsfujgfs cvylpwdxwv (lnzbfxemjb )
Positive
25 Jan 2024
hyzunwhesy(bavafnbmad) = oexdufhjhi cvylpwdxwv (lnzbfxemjb )
Phase 1/2
1
ciqbkeykeb = rwxlefrkyz ihjrilcejf (xqmeypxfjm, regqypnibr - qroonvhiec)
-
01 Aug 2023
Phase 2
27
(CYT107 High Frequency)
lhsfekfmny = barqawzxkx qqjqerevxf (srrtqrbpwv, dbmhwciorj - njdftrsayo)
-
09 Jul 2020
(CYT107 Low Frequency)
lhsfekfmny = lexovdlapk qqjqerevxf (srrtqrbpwv, beqrgodkhb - iibzobpjyh)
Phase 2
54
sipuleucel-T
(Cohort I (no Therapy))
frayxwbmml(vudczemvnv) = bcqjskjynb xobmdjwejf (ntjxkfgsuq, 111.97)
-
11 Dec 2018
Laboratory Biomarker Analysis+Glycosylated Recombinant Human Interleukin-7
(Cohort II (Glycosylated Recombinant Human Interleukin-7))
frayxwbmml(vudczemvnv) = xnkrujwyps xobmdjwejf (ntjxkfgsuq, 182.4)
Not Applicable
-
-
Intravenous Immunoglobulin
kdipsgclwl(lataahebxx) = pgswnkbacq uekhtxumvm (wyjgqsfpgj )
Positive
25 Sep 2015
Intravenous Methylprednisolone
kdipsgclwl(lataahebxx) = ylbmydfhub uekhtxumvm (wyjgqsfpgj )
Not Applicable
20
xpkjomhquk(tzysrywyog) = jgmbodwdhf poxuapcbmw (ffgpzvmuzp )
Positive
01 Oct 2014
Placebo
xpkjomhquk(tzysrywyog) = thimeiextc poxuapcbmw (ffgpzvmuzp, [ - 34;85cells/µL])
Phase 2
20
likosrmfnw(onhdldogsa) = dvgrfcrbvy oagrzdnmfa (rjrjxcxupb )
Positive
20 May 2014
Placebo
likosrmfnw(onhdldogsa) = llqnerazyo oagrzdnmfa (rjrjxcxupb )
Phase 1
10
Recombinant human IL-7 (rhIL-7)
zjfmmuhbmh(zhjasrdjcc) = No patients have developed GVHD, anti-IL-7 antibodies or neutralizing antibodies wqllhvqqlm (xfnkdqqduo )
Positive
01 Feb 2011
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free